Kodiak Sciences KOD 深 沪
等待开盘 06-30 09:30:00 美东时间
37.74
+1.800
+5.01%
华盛通- 最 高38.00
- 今 开35.29
- 成交量 94.15万股
- 最 低 34.63
- 昨 收 35.94
- 总市值 23.62亿
- 52周最高 47.8417
- 市盈率 静 --
- 换手率 1.50%
- 52周最低 3.70
- 委 比 12.69%
- 总股本 6257.84万
- 历史最高 171.21
- 量 比 0.86
- 振 幅 9.38%
- 历史最低 1.37
- 每 手 1
- 风险率 11.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises Inc (NASDAQ:APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Adjusted diluted earnings came in at 57 cents per share, topping the a...
06-26 22:18
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics announced the appointment of Felix J. Baker, PhD, as Chairman of the Board, succeeding Bruce Booth, DPhil, who will remain an Independent Director. Dr. Baker has been a strategic partner since 2024, contributing valuable insights as Kymera advances its pipeline and expands its growth. Dr. Baker, a Managing Member of Baker Brothers Investments, holds advanced degrees in Immunology from Stanford University and serves on multiple...
06-24 20:01
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61
Chardan Capital analyst Daniil Gataulin upgrades Kodiak Sciences (NASDAQ:KOD) from Neutral to Buy and raises the price target from $14 to $61.
05-11 20:11
Kodiak Sciences' KSI-101 MESI Data From Tertiary Care Uveitis Practice Consistent With Phase 1b APEX Study Results
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued
05-01 14:35
Kodiak says Asian MESI cohort data support Phase 3 expansion of KSI-101 program
Kodiak says Asian MESI cohort data support Phase 3 expansion of KSI-101 program Kodiak Sciences scheduled new clinical updates on KSI-101 for macular edema secondary to inflammation at American Uveitis Society on May 2, 2026, with additional data slated for ARVO May 3-7, 2026. Results from tertiary-
05-01 12:24
Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers
The small-cap Russell 2000 punched through to an intraday record high on Friday, capping a furious 13-day rally.
04-18 04:59
Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million
Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million Kodiak Sciences CFO John A. Borgeson exercised stock options for 30,000 shares at USD 1.04 on April 2, 2026. He sold 30,000 shares on April 2, 2026, at weighted-average prices ranging from USD 39.14 to USD 41.77. Direct
04-03 08:27
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics April 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Doordash, Phillips 66 and United Therapeutics, on Thursday. HIGHLIGHTS * Doordash DASH.O : JP Morga
04-02 15:21
PVH, Micron, Intel And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rise, Dow Jones up 400+ points. PVH Corp beats expectations, shares jump 9.9%. Other big gainers include RGC, TH, PLAY, SHAZ, HTT, MFI, RZLV, FSLY, WDC, KOD, LITE, SanDisk.
04-01 23:48
